Eli Lilly (LLY): FY25 Q1 earnings call, May 1, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
11 matches for “Mounjaro”; 5 quoted, at least 25 words apart.
…to Q1 of 2024. Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than $4 billion and now…
…driven by strong volume growth of our key products, including Zepbound and Mounjaro, partially offset by a 7% decline in price. Moving to Europe, revenue…
…Ingelheim. Excluding this benefit, constant currency revenue grew 46%, driven primarily by Mounjaro, partially offset by a 7% decline in price. Japan revenue grew 15%…
…primarily driven by Mounjaro. As a reminder, we recently initiated a limited Mounjaro launch in China with expectation to gradually increase commercial launch in the…
…Kisunla in the next few months. Finally, moving to Cardiometabolic Health, both Mounjaro and Zepbound posted a strong revenue growth. Mounjaro sales were $3.8 billion…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-05-01:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP